Chi-Med Announces Fruquintinib Granted US FDA Fast Track Designation for Metastatic Colorectal Cancer

Hutchison China MediTech Limited announced that the FDA has granted Fast Track Designation for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if RAS wild-type, an anti-epidermal growth factor receptor therapy.